I am not protecting the FDA. I only hope to protect our
I am not protecting the FDA. I only hope to protect our investment is all. My motives only are to the success of Cytodyn. My thoughts were that we may of caused the response that the FDA did with their letter. I can’t say the investors did cause it but it can be construed that way. It’s my interpretation of why the letter was written to slow the attack of the investors. It makes sense but can’t confirm it.
When you have what could be well over a thousand and maybe 10,000 investors writing the FDA and or politicians you don’t know what your going to get. Everybody will write something different and many will not be tactful in the words they choose. Could be downright derogatory with cussing and name calling. Those letters will represent us all as investors. May do more harm than good. Not the wisest response in my opinion.
My interpretation of the events are in the best interest of our investment and nothing more. I have watched the rudeness on the chat boards and can only imagine how nasty some of the letters have been. I personally believe that would be wrong to be nasty to a group of regulators we need to get approvals from in the future. It just doesn’t make sense and using common sense knowing we should not is all I have tried to make known. At this point all I can say is if anyone still has the need to complain directly to the FDA in the future. To be respectful and smart on how you word your letter to not further the alienation of the FDA any further. That is my biggest concern for the future of our company. It would of been better to have one person write a letter and for everyone to sign that letter in support than to have 10,000 what could be nasty letters.
My perception is for the good of the company. I am well aware of the people on not just this board writing some terrible stuff and rallying other to write the FDA and let them have it... so to speak. Explain to me how even 1,000 terribly written letters can help us? Tell me how that would be in the best interest of the company?
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...
Continue Reading
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Your Rights as a DexCom, Inc. Investor The recent developments surrounding DexCom, Inc. (NASDAQ: DXCM) are raising important questions among investors. Rosen Law Firm, a prominent global investor rights law firm, is actively reaching out to stockholders affected by substantial losses during a particular period. The firm has announced that a class action...
Continue Reading
CVS Health Highlights Community Pharmacy Transformation CVS Health (NYSE: CVS) recently released a vital report shedding light on the evolution of community pharmacies. This report signifies the company’s commitment to enhancing pharmacy services and addressing the needs of the community. Insights drawn from a survey conducted by CVS Health and Morning Consult indicate...
Continue Reading
Estée Lauder's Recent Financial Performance Estée Lauder Companies Inc. (NYSE: EL) recently surprised the market with better-than-expected financial results for the first quarter, which contributed to a notable rise in premarket trading. The company's performance reaffirmed positive sales projections for the coming years, revealing a strong start to their fiscal...
Continue Reading
Moderna Faces Market Pressures as Stock Hits Low In a challenging market environment, Moderna Inc. (NASDAQ: MRNA) stock has tragically reached a 52-week low, dipping to $57.71. The biotechnology company is well-known for its innovative mRNA-based vaccines and has found itself grappling with a tumultuous year. Over the past twelve months, Moderna's shares have plummeted by...
Continue Reading
Wolters Kluwer's Exciting Leadership Shift Wolters Kluwer, known for its innovative approach in the fields of healthcare, law, and regulatory solutions, has recently announced a significant leadership change set to unfold in early 2026. After a remarkable journey and a profound impact on the company, Nancy McKinstry has shared her decision to retire from her esteemed role...
Continue Reading